{"success":true,"data":{"pressRelease":{"id":"171949","rtpr_id":"nPreGkP2ka-20261018","ticker":"HLUNA","exchange":"Nasdaq Copenhagen","all_tickers":["HLUNA"],"title":"Changes to the Board of Directors of H. Lundbeck A/S","author":"PR Newswire","published_at":"2026-10-18T17:43:22.858Z","article_body":"Changes to the Board of Directors of H. Lundbeck A/S\nPR Newswire\n\nVALBY, Denmark, Oct. 18, 2026\n* Dorothea Wenzel, Chair of the Board, has informed the Board that she will\nstep down in connection with the Annual General Meeting in 2027. \n* Following the AGM, Lundbeck's Board intends to appoint Lars Fruergaard\nJørgensen as the new Chair.  \n* Effective 10 November 2026, Lars Fruergaard Jørgensen will join the Board\nas an observer, until the formal election. \nVALBY, Denmark, Oct. 18, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck)\nannounces that Dorothea Wenzel has informed Lundbeck's Board of Directors\n(Board) that she will step down in connection with the Annual General Meeting\n(AGM) in 2027. Dorothea joined the Lundbeck Board in 2021 where she served as\nChair of the Audit Committee until she was appointed as the Chair of the Board\nfollowing the AGM in March 2025.  \n\nThe proposed change in Board leadership comes as Lundbeck prepares to enter\nthe next phase of its Focused Innovator strategy. Over the past three years,\nthe company has undergone a significant transformation, strengthening its\ncommercial performance, advancing its pipeline and building a stronger\nfoundation for the future. The upcoming Scale phase of the strategy will focus\non translating these achievements into sustainable long-term growth. \n\nThe Board intends to elect Lars Fruergaard Jørgensen to succeed Dorothea\nWenzel as Chair of the Board. Effective 10 November 2026, Lars will join the\nBoard as an observer until the AGM 2027, at which time he is expected to be\nformally elected as member of the Board, subject to shareholder approval.  \n\nLars Fruergaard Jørgensen is an accomplished pharmaceutical executive with\nmore than 30 years of international experience in the healthcare industry. He\nserved as President and Chief Executive Officer of Novo Nordisk from 2017 to\n2025, following a distinguished career in senior leadership positions across\nthe company's global organization. \n\nDuring his tenure as CEO, he led Novo Nordisk through a period of significant\ngrowth and transformation, strengthening its global leadership in diabetes\ncare and establishing a leading position in obesity treatment. \n\nHe brings extensive expertise in global pharmaceutical strategy, innovation,\ncommercialization, and organizational transformation. He has also served as\nPresident of the European Federation of Pharmaceutical Industries and\nAssociations (EFPIA). He currently chairs the Board of Directors of Healthcare\nDenmark and is a member of the Board of Directors of Danmarks Nationalbank. He\nholds an MSc in Finance and Business Administration from Aarhus University. \n\nLene Skole, Vice Chair, said: \n\"On behalf of the Lundbeck Foundation and the entire Board of Directors of\nLundbeck, I would like to thank Dorothea for her commitment and dedication\nover the past five years. She has been part of the entire transformation\nperiod in different roles at Board level, including the appointment of a new\nCEO in 2023 followed by the launch of Lundbeck's Focused Innovator strategy in\nFebruary 2024. Lundbeck is in a very different and much stronger position\ntoday than just a few years ago. This is a natural moment to look ahead and\nensure continuity in the leadership of the Board as we enter the next phase of\nour journey. I am confident that Lars Fruergaard Jørgensen will bring\nvaluable experience and perspectives to the role, supporting Lundbeck's\ncontinued development and long-term ambitions.\" \n\nDorothea Wenzel, Chair of the Board, said: \n\"It has been an honor and a privilege to serve as the Chair of the Board of\nDirectors of Lundbeck. Lundbeck is a remarkable company, and I am proud of the\ndevelopment the company has undertaken in recent years. Together with the\nBoard, management and our dedicated employees, we have made important progress\nin strengthening the company and positioning it for long-term growth over the\npast five years. As Lundbeck prepares to enter the next phase of its strategy,\nI believe this is a natural time to pass on the responsibility of leading the\nBoard. I am confident in the company's direction and its ability to build on\nthe strong foundation we have established.\" \n\nLars Fruergaard Jørgensen said: \n\"I am excited by the prospect of chairing Lundbeck at such a pivotal moment.\nLundbeck has built a strong foundation in brain health, with a successful\nbusiness, a solid balance sheet, and a pipeline with significant late-stage\npotential. The company has the strength and momentum to step into its next\nphase of growth. I look forward to the opportunity to support that ambition,\ntogether with the Board and the executive leadership team, for the benefit of\npatients, employees and shareholders.\" \n\nThe nominated candidates for the Board of Directors will be included in the\nnotice convening the AGM 2027.\n\nContacts\n\n Jens Høyer                                  Anders Crillesen                                \n Vice President, Head of Investor Relations  Senior Director, External & Internal Relations  \n JSHR@lundbeck.com                           AECE@lundbeck.com                               \n +45 30 83 45 01                             +45 27 79 12 86                                 \n                                                                                             \n\nAbout H. Lundbeck A/S\n\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world's population, and the effects\nare felt throughout society. With the rapidly improving understanding of the\nbiology of the brain, we hold ourselves accountable for advancing brain health\nby curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect\nwith us via LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4800419-1&h=372511470&u=https%3A%2F%2Feur01.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Flundbeck%252F%26data%3D05%257C02%257CMJKJ%2540lundbeck.com%257C7e687e1221b94185debd08de3277246a%257Cca625151ac0044419024c88fad6084da%257C0%257C0%257C639003684489901459%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DbX5GpFb8H21rowTneq%252F9LeTO3NOBPtbwAlN56ldlUwk%253D%26reserved%3D0&a=LinkedIn).\n\nCONTACT: \nH. Lundbeck A/S\nOttiliavej 9, 2500 Valby, Denmark\n+45 3630 1311\ninfo@lundbeck.com\n\nThis information was brought to you by Cision http://news.cision.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/changes-to-the-board-of-directors-of-h--lundbeck-a-s,c4410281\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/18215/4410281/4323501.pdf  Company Announcement_Final  \n\n \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/changes-to-the-board-of-directors-of-h-lundbeck-as-302911999.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPreGkP2ka-20261018","title":"Changes to the Board of Directors of H. Lundbeck A/S","author":"PR Newswire","ticker":"HLUNA","created":"2026-10-18T17:43:22.858Z","tickers":["HLUNA"],"exchange":"Nasdaq Copenhagen","article_body":"Changes to the Board of Directors of H. Lundbeck A/S\nPR Newswire\n\nVALBY, Denmark, Oct. 18, 2026\n* Dorothea Wenzel, Chair of the Board, has informed the Board that she will\nstep down in connection with the Annual General Meeting in 2027. \n* Following the AGM, Lundbeck's Board intends to appoint Lars Fruergaard\nJørgensen as the new Chair.  \n* Effective 10 November 2026, Lars Fruergaard Jørgensen will join the Board\nas an observer, until the formal election. \nVALBY, Denmark, Oct. 18, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck)\nannounces that Dorothea Wenzel has informed Lundbeck's Board of Directors\n(Board) that she will step down in connection with the Annual General Meeting\n(AGM) in 2027. Dorothea joined the Lundbeck Board in 2021 where she served as\nChair of the Audit Committee until she was appointed as the Chair of the Board\nfollowing the AGM in March 2025.  \n\nThe proposed change in Board leadership comes as Lundbeck prepares to enter\nthe next phase of its Focused Innovator strategy. Over the past three years,\nthe company has undergone a significant transformation, strengthening its\ncommercial performance, advancing its pipeline and building a stronger\nfoundation for the future. The upcoming Scale phase of the strategy will focus\non translating these achievements into sustainable long-term growth. \n\nThe Board intends to elect Lars Fruergaard Jørgensen to succeed Dorothea\nWenzel as Chair of the Board. Effective 10 November 2026, Lars will join the\nBoard as an observer until the AGM 2027, at which time he is expected to be\nformally elected as member of the Board, subject to shareholder approval.  \n\nLars Fruergaard Jørgensen is an accomplished pharmaceutical executive with\nmore than 30 years of international experience in the healthcare industry. He\nserved as President and Chief Executive Officer of Novo Nordisk from 2017 to\n2025, following a distinguished career in senior leadership positions across\nthe company's global organization. \n\nDuring his tenure as CEO, he led Novo Nordisk through a period of significant\ngrowth and transformation, strengthening its global leadership in diabetes\ncare and establishing a leading position in obesity treatment. \n\nHe brings extensive expertise in global pharmaceutical strategy, innovation,\ncommercialization, and organizational transformation. He has also served as\nPresident of the European Federation of Pharmaceutical Industries and\nAssociations (EFPIA). He currently chairs the Board of Directors of Healthcare\nDenmark and is a member of the Board of Directors of Danmarks Nationalbank. He\nholds an MSc in Finance and Business Administration from Aarhus University. \n\nLene Skole, Vice Chair, said: \n\"On behalf of the Lundbeck Foundation and the entire Board of Directors of\nLundbeck, I would like to thank Dorothea for her commitment and dedication\nover the past five years. She has been part of the entire transformation\nperiod in different roles at Board level, including the appointment of a new\nCEO in 2023 followed by the launch of Lundbeck's Focused Innovator strategy in\nFebruary 2024. Lundbeck is in a very different and much stronger position\ntoday than just a few years ago. This is a natural moment to look ahead and\nensure continuity in the leadership of the Board as we enter the next phase of\nour journey. I am confident that Lars Fruergaard Jørgensen will bring\nvaluable experience and perspectives to the role, supporting Lundbeck's\ncontinued development and long-term ambitions.\" \n\nDorothea Wenzel, Chair of the Board, said: \n\"It has been an honor and a privilege to serve as the Chair of the Board of\nDirectors of Lundbeck. Lundbeck is a remarkable company, and I am proud of the\ndevelopment the company has undertaken in recent years. Together with the\nBoard, management and our dedicated employees, we have made important progress\nin strengthening the company and positioning it for long-term growth over the\npast five years. As Lundbeck prepares to enter the next phase of its strategy,\nI believe this is a natural time to pass on the responsibility of leading the\nBoard. I am confident in the company's direction and its ability to build on\nthe strong foundation we have established.\" \n\nLars Fruergaard Jørgensen said: \n\"I am excited by the prospect of chairing Lundbeck at such a pivotal moment.\nLundbeck has built a strong foundation in brain health, with a successful\nbusiness, a solid balance sheet, and a pipeline with significant late-stage\npotential. The company has the strength and momentum to step into its next\nphase of growth. I look forward to the opportunity to support that ambition,\ntogether with the Board and the executive leadership team, for the benefit of\npatients, employees and shareholders.\" \n\nThe nominated candidates for the Board of Directors will be included in the\nnotice convening the AGM 2027.\n\nContacts\n\n Jens Høyer                                  Anders Crillesen                                \n Vice President, Head of Investor Relations  Senior Director, External & Internal Relations  \n JSHR@lundbeck.com                           AECE@lundbeck.com                               \n +45 30 83 45 01                             +45 27 79 12 86                                 \n                                                                                             \n\nAbout H. Lundbeck A/S\n\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world's population, and the effects\nare felt throughout society. With the rapidly improving understanding of the\nbiology of the brain, we hold ourselves accountable for advancing brain health\nby curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect\nwith us via LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4800419-1&h=372511470&u=https%3A%2F%2Feur01.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Flundbeck%252F%26data%3D05%257C02%257CMJKJ%2540lundbeck.com%257C7e687e1221b94185debd08de3277246a%257Cca625151ac0044419024c88fad6084da%257C0%257C0%257C639003684489901459%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DbX5GpFb8H21rowTneq%252F9LeTO3NOBPtbwAlN56ldlUwk%253D%26reserved%3D0&a=LinkedIn).\n\nCONTACT: \nH. Lundbeck A/S\nOttiliavej 9, 2500 Valby, Denmark\n+45 3630 1311\ninfo@lundbeck.com\n\nThis information was brought to you by Cision http://news.cision.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/changes-to-the-board-of-directors-of-h--lundbeck-a-s,c4410281\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/18215/4410281/4323501.pdf  Company Announcement_Final  \n\n \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/changes-to-the-board-of-directors-of-h-lundbeck-as-302911999.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-18T17:43:22.913443467Z","server_sent_at_ms":1792345402913},"received_at":"2026-10-18T17:43:22.971Z","source_url":null},"analysis":{"id":"160097","press_release_id":"171949","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["board chair transition requires shareholder approval at AGM 2027; interim observer role until then"],"eventType":"board_change","narrative":"H. Lundbeck announced that Board Chair Dorothea Wenzel will step down at the 2027 AGM, with the board intending to elect Lars Fruergaard Jørgensen as her successor.\n\nJørgensen, Novo Nordisk's CEO from 2017 to 2025, joins the board as an observer effective 10 November 2026 ahead of formal election subject to shareholder approval.\n\nThe transition is framed as continuity as Lundbeck enters the Scale phase of its Focused Innovator strategy; the appointment of a high-profile pharma executive is broadly a confidence signal rather than a disruptive change.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Former Novo Nordisk CEO to chair Lundbeck -- marquee governance appointment signals continuity into the Scale phase of strategy."},"keyFigures":{},"quotedText":"Lundbeck has built a strong foundation in brain health, with a successful business, a solid balance sheet, and a pipeline with significant late-stage potential.","namedEntities":{"people":[{"name":"Dorothea Wenzel","role":"Chair of the Board (stepping down at AGM 2027)"},{"name":"Lars Fruergaard Jørgensen","role":"Board observer from 10 Nov 2026; proposed successor as Chair; former CEO of Novo Nordisk (2017-2025)"},{"name":"Lene Skole","role":"Vice Chair of the Board"}],"products":[],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA","relationship":"filer"},{"name":"Novo Nordisk","relationship":"former employer of incoming chair"},{"name":"Lundbeck Foundation","relationship":"foundation shareholder referenced"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Planned, orderly board chair transition with a named high-profile successor (former Novo Nordisk CEO) months in advance. Low operational risk and framed as continuity, but a notable governance event given the marquee appointment."},"tickerRelevance":{"others":[],"primary":"HLUNA"},"globalImportance":25,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap international pharma","eventGravity":"planned board chair succession with named high-profile successor","issuerAuthored":true,"householdBrandBoost":"Novo Nordisk name recognition modestly lifts attention"}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"H. Lundbeck announced that Board Chair Dorothea Wenzel will step down at the 2027 AGM, with the board intending to elect Lars Fruergaard Jørgensen as her successor.\n\nJørgensen, Novo Nordisk's CEO from 2017 to 2025, joins the board as an observer effective 10 November 2026 ahead of formal election subject to shareholder approval.\n\nThe transition is framed as continuity as Lundbeck enters the Scale phase of its Focused Innovator strategy; the appointment of a high-profile pharma executive is broadly a confidence signal rather than a disruptive change.","key_figures":{},"named_entities":{"people":[{"name":"Dorothea Wenzel","role":"Chair of the Board (stepping down at AGM 2027)"},{"name":"Lars Fruergaard Jørgensen","role":"Board observer from 10 Nov 2026; proposed successor as Chair; former CEO of Novo Nordisk (2017-2025)"},{"name":"Lene Skole","role":"Vice Chair of the Board"}],"products":[],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA","relationship":"filer"},{"name":"Novo Nordisk","relationship":"former employer of incoming chair"},{"name":"Lundbeck Foundation","relationship":"foundation shareholder referenced"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-18T17:43:28.236Z","global_importance":25,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap international pharma","eventGravity":"planned board chair succession with named high-profile successor","issuerAuthored":true,"householdBrandBoost":"Novo Nordisk name recognition modestly lifts attention"}},"durationMs":5251,"modelName":"glm-5.3-flashx"}}